Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IFx 2.0

Next Previous
Drug Profile

IFx 2.0

Alternative Names: Autologous whole-cell ImmuneFx™ cancer vaccine therapy; Emm55 Streptococcal antigen pDNA; IFx-Hu2.0; pDNA Intralesional cancer vaccine

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Morphogenesis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; TuHURA Biosciences
  • Class Antineoplastics; Cancer vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Merkel cell carcinoma
  • Phase I Basal cell cancer; Malignant melanoma; Squamous cell cancer

Most Recent Events

  • 24 Jun 2025 Phase-III clinical trials in Merkel cell carcinoma (Metastatic disease, First-line therapy, Adjunctive treatment, Late-stage disease) in USA (Intralesional) (NCT06947928)
  • 09 Jun 2025 TuHURA Biosciences plans a phase-III registration trial for Merkel Cell Carcinoma (First-line therapy, Adjunctive treatment, Metastatic disease, Late-stage disease) in USA (Intralesional, Injection) in June 2025 (TuHURA Bio Pipeline, March 2025) (NCT06947928)
  • 30 Apr 2025 Phase-I clinical trials in Merkel cell carcinoma (Adjunctive treatment, Recurrent, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy) (Intralesional) (NCT06940440)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top